Table 2.
Responder analysis in patients aged ≥ 65 yearsa (full analysis set)
Analysis, n (%) | Placebo (N = 220) | Vibegron (N = 242) | Tolterodine (N = 166) |
---|---|---|---|
≥ 75% reduction in UUI episodesb | 50 (29.8) | 96 (50.0)** | 55 (43.0)* |
50% reduction in urgency episodes | 63 (28.8) | 94 (38.7)* | 49 (29.5) |
UUI urge urinary incontinence
aOn a 7-day diary at week 12
bFull analysis set for incontinence (placebo, N = 168; vibegron, N = 192; tolterodine, N = 128)
*P < 0.05; **P < 0.001 vs. placebo